ArticleDigestive diseases and sciences1998
Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.
Article in Digestive diseases and sciences, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 86 citations in OpenAlex.
- Low-Grade Activation of the Extrinsic Coagulation Pathway in Patients with Ulcerative Colitis.Digestive diseases and sciences · 2024Article
- International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2021Article
- Venous and arterial thromboembolism in patients with inflammatory bowel diseases.World journal of gastroenterology · 2021Review
- Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases.International journal of molecular sciences · 2021Review
- Bullous Pemphigoid: Trigger and Predisposing Factors.Biomolecules · 2020Review
- Budd-Chiari syndrome: a rare and life-threatening complication of Crohn's disease.BMJ case reports · 2018Article
- Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration.Frontiers in immunology · 2017Review
- Anti Saccharomyces cerevisiae Antibodies in Patients With Anti-β2 Glycoprotein I Antibodies.Journal of clinical laboratory analysis · 2016Article
- Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.World journal of gastroenterology · 2015Article
- Thromboembolic complications in inflammatory bowel disease.Journal of thrombosis and thrombolysis · 2015Review
- Epidemiology, risk factors and management of cardiovascular diseases in IBD.Nature reviews. Gastroenterology & hepatology · 2015Review
- Thrombosis in inflammatory bowel diseases: what's the link?Thrombosis journal · 2015Article
- Venous thrombosis and prothrombotic factors in inflammatory bowel disease.World journal of gastroenterology · 2014Review
- Inflammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability.World journal of gastroenterology · 2014Review
- Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases.International journal of colorectal disease · 2013Article
- Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events.World journal of gastroenterology · 2009Article
- Autoantibodies in primary sclerosing cholangitis.World journal of gastroenterology · 2008Review
- Relationship and significance between anti-beta2-glycoprotein I antibodies and platelet activation state in patients with ulcerative colitis.World journal of gastroenterology · 2008Article
- Crohn's and Behçet's disease association presenting with superior vena cava thrombosis.Digestive diseases and sciences · 2005Article
- Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia.Digestive diseases and sciences · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with inflammatory bowel disease (IBD) frequently suffer from thromboembolic events. Anti-cardiolipin (aCL) antibodies have been shown to be associated with thrombosis. Recently, the antibodies against the anti-cardiolipin cofactor beta2-glycoprotein I (a(beta2)GPI) have been found with higher specificity for thrombosis. The presence of these antibodies was assessed in 128 patients with IBD [83 with ulcerative colitis (UC) and 45 with Crohn's disease (CD)] and 100 healthy controls (blood donors). Patients with UC and CD had a significantly higher prevalence of aCL (18.1% and 15.6%, respectively) than healthy controls (HC) (3%). Eleven IBD patients (8.6%) but no HC had a(beta2)GPI. None of the IBD patients with a history of thrombosis had aCL and only one of them (a UC patient with deep vein thrombosis of the right leg) had a high titer of IgG a(beta2)GPI. In conclusion, these data show that both aCL and a(beta2)GPI are significantly associated with IBD but further studies are needed to determine the significance of our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.